Recursion Pharma Q3 Net Loss Narrows, Reports Positive REC-4881 Data; Advances Pipeline
Recursion Pharmaceuticals (RXRX) reported Q3 2026 net loss narrowed to $119.0M from $162.3M YoY. Revenue rose to $18.55M, driven by a $10M Sanofi milestone payment. REC-4881 showed positive FAP trial results, with significant polyp burden reductions. REC-1245 demonstrated preliminary efficacy in cancers. RXRX expects cash to last into 2029. Stock is down 4.96% to $3.83.
How this was made
The 30-second read
Why it matters
The Q3 earnings beat revenue expectations and the REC-4881 data provide a catalyst that could improve short‑term price action.
Market read
Positive earnings and early trial data create a short‑term buying opportunity for RXRX.
What to watch
Potential dilution from future financing needs and reliance on partnership milestones.
Background
Recursion Pharma (RXRX) is a clinical‑stage AI‑enabled drug discovery company with collaborations with Sanofi, Roche and Genentech.
Ticker impact
Recursion Pharma reported Q3 net loss narrowing, revenue rise and positive Phase 1b/2 data for REC-4881, indicating clinical progress and cash runway.
likely upward as investors price in the encouraging data and extended cash runway
First report of Phase 1b/2 results for a rare‑disease candidate and a narrower loss, both material for a biotech micro‑cap.
Market effects
Strengthens the AI‑driven biotech sector narrative and may boost peer sentiment.
Limited to US biotech investors; no broader regional effect.
Modest global relevance, primarily affecting biotech and AI‑drug discovery niche.
Counterpoint
The data are early‑stage; investors may remain cautious until later‑stage trials.
Key entities
- companyRecursion Pharmaceuticals, Inc.
AI‑driven biotech reporting Q3 results and trial data.
- personFred Hassan
Newly appointed Chair of the Board.




